Michel Doepke
@doepke_michel
Followers
5K
Following
1K
Media
2K
Statuses
5K
Der Account von Michel Doepke, Redakteur beim @aktionaer
Kulmbach
Joined January 2021
$ITCI $SWTX and $BPMC gone. I will add three new commercial stage biotechs to this potential M&A list:.$TGTX - MS, product: Briumvi.$DAWN - Oncology, product: Ojemda.$BBIO - rare, genetic diseases / oncology, product: Attruby/Beyonttra.
$ITCI gone - $SWTX next? Also $AXSM - lifted patent overhang should be really supportive for a potential M&A deal.
6
9
66
$AZN TAGRISSO (osimertinib)plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
businesswire.com
Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition ...
1
1
9
$NUVB Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire.com
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and up...
0
0
8
$JNJ Data published in The New England Journal of Medicine demonstrate RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
prnewswire.com
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy...
0
0
1
$NUVL Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025.
prnewswire.com
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
1
0
1
$SMMT Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC. $BNTX $BMY $PFE
businesswire.com
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potenti...
0
2
16
$BMRN Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
prnewswire.com
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALYNZIQ® (pegvaliase-pqpz) for...
0
2
11
RT @HOThomasWPhelps: @A_May_MD Further building on @A_May_MD work, I keep chart comparing PBO-adjusted EASI data for AD trials and you can….
0
3
0
$NKTR 52-week high. 📈📈📈 $SNY
Back in $NKTR today. $SNY disappointment should create additional value in the short term. #Rezpeg has new mechanism of action. Market cap: Just ~$550M.
2
1
13
$VSTM trimmed ahead of GenFleet data presentation on Sunday.
investor.verastem.com
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evalua...
$VSTM moving. Still own the whole position despite the setback below $5. Undervalued imo.
1
0
0
$XBI 📈📈📈.
Traders now pricing in a 99% chance of a rate cut in September
1
1
2
At the end of February, $MLYS shares were trading at around $10. 👇.Offering this week at $25.50, shares are trading now around $33. Great story, good data so far. $AZN.
$MLYS interesting company with important catalysts ahead: topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025.
2
0
3
$NKTR analyst reactions from yesterday. Piper: $SNY data demonstrated “relatively underwhelming efficacy” compared to NKTR’s drug, REZPEG. “Ultimately, we believe this reiterates REZPEG’s differentiated profile, further substantiating its competitive commercial potential across.
Back in $NKTR today. $SNY disappointment should create additional value in the short term. #Rezpeg has new mechanism of action. Market cap: Just ~$550M.
2
4
25
$CGON Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
globenewswire.com
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder...
0
1
2
$QURE Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease. $SGMO
globenewswire.com
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first...
2
0
9
$BNTX and DualityBio Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer.
investors.biontech.de
Trastuzumab pamirtecan (BNT323/DB-1303), an investigational next-generation antibody drug-conjugate (“ADC”) targeting HER-2, met its primary endpoint of progression free survival (“PFS”) in interim...
0
2
17
Study of $MDT Hugo robotic-assisted surgery system in hernia repair meets safety and effectiveness endpoints. $ISRG
news.medtronic.com
First-ever investigational device exemption clinical study for robotic-assisted hernia repair in the U.S. presented at the American Hernia Society annual meeting GALWAY, Ireland and NASHVILLE, Tenn.,
0
1
1
$NVO $NOVOB #NovoNordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the #EASD25 #diabetes congress. $LLY
globenewswire.com
The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect...
0
0
3
RT @doepke_michel: Patience 🙏 $VSTM up ~60% in one month. Still own the whole position. Shares under $5 were a gift! 👇 .
0
1
0